Radioligand therapy using [(177)Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis.
Eur J Nucl Med Mol Imaging. 2020 Aug;47(9):2106-2112. doi: 10.1007/s00259-020-04703-3. Epub 2020 Feb 16.
Eur J Nucl Med Mol Imaging. 2020.
PMID: 32062682
Free PMC article.
Various studies have evaluated the efficacy and safety of [(177)Lu]Lu-PSMA-617 using a dose of 6.0 GBq and an 8-week therapy interval. ...However, future studies are needed to elucidate the dose-related efficacy of [(177)Lu]Lu-PSMA-617 as a way to pers …
Various studies have evaluated the efficacy and safety of [(177)Lu]Lu-PSMA-617 using a dose of 6.0 GBq and an 8-week therapy i …